Skip to main content
. 2021 Jun 7;16:98. doi: 10.1186/s13014-021-01822-5

Fig. 1.

Fig. 1

The probit model [17] of Grade 2–4 Brachial Plexopathy shows the Dmax values of the Karolinska and Indiana University (IU) datasets [1, 2] with red squares denoting the cases corresponding to CTCAE grade 2 or higher adverse events (AE), blue dots representing the cases without AE, and quartiles plotted as the four blue bars. According to the model in 3–4 fractions, the risk of a brachial plexopathy with the dose of 26 Gy is 10%, whereas the 25% and 50% risk levels correspond to 47 and 70 Gy respectively